Invitation to MorphoSys' First Quarter 2023 Financial Results Conference ... 2023-04-27
Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference ...
Source: pr-inside.com
📰 Thomas Biegi News
Page 4 - Thomas Biegi News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Thomas Biegi. Real-time updates on events, politics, business and more.
MorphoSys AG: Invitation to MorphoSys' First Quarter 2023 Financial Results Conference Call on May 4, 2023
Conference Call AlertMUNICH, GERMANY / ACCESSWIRE / April 27, 2023 / MorphoSys AG (FSE:MOR)(NASDAQ:MOR) will publish its results for the first quarter 2023 on May 3, 2023 at 10:00 pm CEST (09:00 pm BST
Source: finanznachrichten.de
Invitation to MorphoSys' First Quarter 2023 Financial Results Conference Call on May 4, 2023
EQS-News: MorphoSys AG / Key word: Quarter Results Invitation to MorphoSys’ First Quarter 2023 Financial Results Conference Call on May 4, 2023 27.04.2023 / 22:03... | June 18, 2023
Source: marketscreener.com
Incyte and MorphoSys U.S. Inc.: MorphoSys and Incyte Announce Five-Year Results of L-MIND Study Showed Prolonged, Durable Responses in Relapsed or Refractory DLBCL Patients Treated with Monjuvi (tafasitamab-cxix)
Results from the Phase 2 L-MIND study were highlighted as a late-breaking oral presentation at the American Association for Cancer Research Annual Meeting 2023 MorphoSys U.S. Inc., a fully owned subsidiary
Source: finanznachrichten.de
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
EQS-News: MorphoSys AG / Key word: Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023... | April 4, 2023
Source: marketscreener.com
MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topli
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CESTThe issuer is solely responsible for the content of this announcement.Media ReleasePlanegg/Munich, Germa...
Source: pharmiweb.com
EQS-News: MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023
04.04.2023 - EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys Completes Enrollment of Phase 3 MANIFEST-2 Study of Pelabresib in Myelofibrosis with Topline Results Expected by End of 2023 04.04.2023 / 22:01 CET/CEST The issuer is solely responsible ...
Source: wallstreet-online.de
EQS-News: MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG / Key word(s): Miscellaneous MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (IS...
Source: businessinsider.com
MorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6)
EQS-News: MorphoSys AG / Key word(s): MiscellaneousMorphoSys AG: Repurchase of portion of outstanding convertible bonds due 2025 (ISIN DE000A3H2XW6) 24.03.2023 / 17:00 CET/CESTThe issuer is solely responsible for the content of this announcement.NOT FOR DISTRIBUTION IN OR INTO, OR TO ANY PERSON LOCATED OR RESIDENT I...
Source: pharmiweb.com
EQS-News: MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Provides Corporate Update
EQS-News: MorphoSys AG / Key word(s): Annual Report MorphoSys AG Reports Fourth Quarter and Full Year 2022 Financial Results and Prov...
Source: businessinsider.com